CRISPR Technology in Neurodegenerative Disease Research: A Focus on Alzheimer's
DOI:
https://doi.org/10.58445/rars.2273Keywords:
CRISPR, Alzheimer'sAbstract
Neurodegenerative diseases, among which is Alzheimer's disease, are among the biggest challenges for modern medicine due to their progressive nature and lack of curative treatment approaches. Recent advances in CRISPR-Cas9 technology introduce new possibilities for editing of disease-associated genetic risk factors in iPSCs, thereby offering a therapeutic solution. The current review summarizes the contemporary understanding of CRISPR-based gene editing in iPSCs in relation to their usage for generating neurons resistant to neurodegeneration. Key targets, methodologies, challenges, and future directions are discussed, highlighting the potential of CRISPR in research and therapy for neurodegenerative diseases.
References
Barman, N. C., et al. "CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease-A Narrative Review." Neurology and Therapy, vol. 9, 2020,
pp. 419-34, https://link.springer.com/article/10.1007/s40120-020-00218-z.
D'SOUZA, R. U. S. S. E. L. L., et al. "A Scoping Review on the Ethical Issues in the Use of CRISPR-Cas9 in the Creation of Human Disease Models." Journal of Clinical & Diagnostic Research, vol. 17, no. 12, 2023, Russell Franco Dâ€TMSouza, et al. “A Scoping Review on the Ethical Issues in the Use of CRISPR-Cas9 in the Creation of Human Disease Models.” Journal of Clinical and Diagnostic Research, vol. 17, no. 12, 1 Jan. 2023, https://doi.org/10.7860/jcdr/2023/68275.18809.
Konstantinidis, E., et al. "CRISPR-Cas9 Treatment Partially Restores Amyloid-ẞ 42/40 in Human Fibroblasts with the Alzheimer's Disease PSEN1 M146L Mutation." Molecular Therapy-Nucleic Acids, vol. 28, 2022, pp. 450-61, https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(22)00071-3
Raikwar, S. P., et al. "Next Generation Precision Medicine: CRISPR-Mediated Genome Editing for the Treatment of Neurodegenerative Disorders." Journal of
Neuroimmune Pharmacology, vol. 14, 2019, pp. 608-41, https://link.springer.com/article/10.1007/s11481-019-09849-y.
Sen, T., and R. P. Thummer. "CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and
Therapeutics." Neurotoxicity Research, vol. 40, no. 5, 2022, pp. 1597-623, https://link.springer.com/article/10.1007/s12640-022-00564-w.
Valadez-Barba, V., et al. "iPSC for Modeling Neurodegenerative Disorders." Regenerative Therapy, vol. 15, 2020, pp. 332-39,
https://www.sciencedirect.com/science/article/pii/S2352320420300894.
Sajid, et al. “SiRNA Drug Delivery across the Blood–Brain Barrier in Alzheimer’s Disease.” Advanced Drug Delivery Reviews, vol. 199, 1 Aug. 2023, pp. 114968–114968, https://doi.org/10.1016/j.addr.2023.114968.
Aslam, A., et al. "CRISPR Advancements in Correcting Protein Misfolding: Implications
for Neurodegenerative Disorders." Gene Expression, vol. 23, no. 4, 2024, pp. 309- 35, https://www.xiahepublishing.com/m/1555-3884/GE-2024-00002.
Additional Files
Posted
Categories
License
Copyright (c) 2025 Harrini Vinoth Kumar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.